The study by Lehman and colleagues assessed the expression of several immune function and activity markers on three subsets of monocytes: classical (CD14+ CD16− SLAN−), intermediate (CD14+ CD16+ SLAN−), and non-classical (CD14low/− CD16+ SLAN+) from glioma patients (15 out of 24 were glioblastoma) and healthy individuals [104]. This evidence concerns the gene SECISBP2L and glioma.